Molecular signatures of chronic myeloid leukemia stem cells

Biomarker Research

Volumn 1, Issue 1, 2013, Pages

  Chen, Yaoyu ^a   Li, Shaoguang ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

BCR ABL; Biomarker; Cancer stem cells; CML; Hematopoietic stem cells; Leukemic stem cells

Indexed keywords

ACYL COENZYME A DESATURASE; ARACHIDONATE 5 LIPOXYGENASE; BCR ABL PROTEIN; DASATINIB; GLYCOGEN SYNTHASE KINASE 3BETA; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; PROTEIN TYROSINE KINASE; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

CANCER STEM CELL; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84901996626     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-1-21     Document Type: Review

References (53)

1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Eng J Med 2001, 344:1038-1042.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Eng J Med 2001, 344:1031-1037.
3. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med 2006, 355:2408-2417.
4. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056-2064.
5. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325. 10.1182/blood.V99.1.319, 11756187.
6. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60. 10.1182/blood-2006-03-011239, 16973963.
7. Chen Y, Peng C, Sullivan C, Li D, Li S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 2010, 24:1545-1554. 10.1038/leu.2010.143, 3130198, 20574455.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
9. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Eng J Med 2006, 355:1253-1261.
10. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003, 3:895-902. 10.1038/nrc1232, 14737120.
11. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111. 10.1038/35102167, 11689955.
12. Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell 2008, 132:681-696. 10.1016/j.cell.2008.01.036, 18295583.
13. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2009, 17:219-230. 10.1038/mt.2008.254, 2835048, 19066601.
14. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999, 189:1399-1412. 10.1084/jem.189.9.1399, 2193055, 10224280.
15. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006, 103:16870-16875. 10.1073/pnas.0606509103, 1629087, 17077147.
16. Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program 2001, 2001:87-112.
17. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101:4701-4707. 10.1182/blood-2002-09-2780, 12576334.
18. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011, 121:396-409. 10.1172/JCI35721, 3007128, 21157039.
19. Peters-Golden M, Henderson WR. Leukotrienes. N Eng J Med 2007, 357:1841-1854.
20. Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009, 41:783-792. 10.1038/ng.389, 2887745, 19503090.
21. Scaglia N, Igal RA. Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J Biol Chem 2005, 280:25339-25349. 10.1074/jbc.M501159200, 15851470.
22. Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, Sullivan C, Cerny J, Hutchinson L, Higgins A, et al. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet 2012, 44:861-871. 10.1038/ng.2350, 3408839, 22797726.
23. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998, 17:1371-1384. 10.1093/emboj/17.5.1371, 1170485, 9482734.
24. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Eng J Med 2004, 351:657-667.
25. Correa S, Binato R, Du Rocher B, Castelo-Branco MT, Pizzatti L, Abdelhay E. Wnt/beta-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer 2012, 12:303. 10.1186/1471-2407-12-303, 3464798, 22823957.
26. Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010, 18:74-87. 10.1016/j.ccr.2010.04.025, 2904512, 20609354.
27. Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 2013, 121:1824-1838. 10.1182/blood-2012-02-412890, 23299311.
28. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653. 10.1126/science.1186624, 3084586, 20339075.
29. Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P, Trussell C, Schmitt-Graeff A, Landwerlin K, Veelken H, Warmuth M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238-249. 10.1016/j.ccr.2008.08.003, 18772113.
30. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009, 4:559-567. 10.1016/j.stem.2009.03.016, 3065323, 19497284.
31. Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S, El Andaloussi A, Nimer SD, Kee BL, Taichman R, et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 2009, 4:548-558. 10.1016/j.stem.2009.03.015, 2914688, 19497283.
32. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458:776-779. 10.1038/nature07737, 2946231, 19169242.
33. Hayette S, Chabane K, Michallet M, Michallat E, Cony-Makhoul P, Salesse S, Maguer-Satta V, Magaud JP, Nicolini FE. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res 2011, 35:38-43. 10.1016/j.leukres.2010.06.030, 20673586.
34. Pelletier SD, Hong DS, Hu Y, Liu Y, Li S. Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice. Blood 2004, 104:2163-2171. 10.1182/blood-2003-09-3033, 15213099.
35. Rossi DJ, Bryder D, Zahn JM, Ahlenius H, Sonu R, Wagers AJ, Weissman IL. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci USA 2005, 102:9194-9199. 10.1073/pnas.0503280102, 1153718, 15967997.
36. Sullivan C, Chen Y, Shan Y, Hu Y, Peng C, Zhang H, Kong L, Li S. Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells. PLoS One 2011, 6:e26246. 10.1371/journal.pone.0026246, 3200313, 22039451.
37. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006, 12:1175-1180. 10.1038/nm1489, 16998483.
38. Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001, 153:1277-1286. 10.1083/jcb.153.6.1277, 2192031, 11402070.
39. Du J, Liu Y, Meline B, Kong G, Tan LX, Lo JC, Wang J, Ranheim E, Zhang L, Chang YI, et al. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals. Leukemia 2013, 27:754-757. 10.1038/leu.2012.251, 3602969, 22976127.
40. Chen Y, Wang X, Ben J, Yue S, Bai H, Guan X, Bai X, Jiang L, Ji Y, Fan L, Chen Q. The di-leucine motif contributes to class a scavenger receptor-mediated internalization of acetylated lipoproteins. Arterioscler Thromb Vasc Biol 2006, 26:1317-1322. 10.1161/01.ATV.0000220171.50282.0c, 16574888.
41. Chen Y, Sullivan C, Peng C, Shan Y, Hu Y, Li D, Li S. A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia. Blood 2011, 118:390-400. 10.1182/blood-2010-11-316760, 3138690, 21596859.
42. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, Nakao S, Motoyama N, Hirao A. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010, 463:676-680. 10.1038/nature08734, 20130650.
43. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, de Mattos Fernandez S, Wymann MP, Brosens JJ, Schulze A, Lam EW. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 2008, 28:5886-5898. 10.1128/MCB.01265-07, 2547013, 18644865.
44. Wang Y, Liu Y, Malek SN, Zheng P. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8:399-411. 10.1016/j.stem.2011.02.006, 3084595, 21474104.
45. Zhang H, Li H, Xi HS, Li S. HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 2012, 119:2595-2607. 10.1182/blood-2011-10-387381, 3311277, 22275380.
46. Peng C, Chen Y, Yang Z, Zhang H, Osterby L, Rosmarin AG, Li S. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 2010, 115:626-635. 10.1182/blood-2009-06-228130, 2810991, 19965668.
47. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, Pernis A, Pasqualucci L, Dalla-Favera R. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007, 12:280-292. 10.1016/j.ccr.2007.08.011, 17785208.
48. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011, 473:384-388. 10.1038/nature09883, 3597744, 21593872.
49. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002, 108:165-170. 10.1016/S0092-8674(02)00626-8, 11832207.
50. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP. PML is essential for multiple apoptotic pathways. Nat Genet 1998, 20:266-272. 10.1038/3073, 9806545.
51. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072-1078. 10.1038/nature07016, 2712082, 18469801.
52. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001, 353:417-439. 10.1042/0264-6021:3530417, 1221586, 11171037.
53. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8:355-368. 10.1016/j.ccr.2005.10.015, 16286244.